Recent Analysts’ Ratings Changes for Gilead Sciences (GILD)

A number of firms have modified their ratings and price targets on shares of Gilead Sciences (NASDAQ: GILD) recently:

• 6/9/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 6/8/2026 – Gilead Sciences had its “sector perform” rating reaffirmed by Royal Bank Of Canada.
• 6/1/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Royal Bank Of Canada. They now have a $122.00 price target on the stock.
• 6/1/2026 – Gilead Sciences was upgraded by Royal Bank Of Canada from “hold” to “moderate buy”.
• 5/28/2026 – Gilead Sciences was downgraded by Weiss Ratings from “buy (b)” to “buy (b-)”.
• 5/20/2026 – Gilead Sciences was upgraded by Maxim Group from “hold” to “buy”. They now have a $165.00 price target on the stock.
• 5/19/2026 – Gilead Sciences had its price target lowered by Daiwa Securities Group Inc. from $161.00 to $150.00. They now have an “outperform” rating on the stock.
• 5/11/2026 – Gilead Sciences was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 5/11/2026 – Gilead Sciences had its price target lowered by Rothschild & Co Redburn from $170.00 to $167.00.
• 5/9/2026 – Gilead Sciences was downgraded by Wall Street Zen from “strong-buy” to “hold”.
• 5/8/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $175.00 to $168.00.
• 5/8/2026 – Gilead Sciences had its price target lowered by Leerink Partners from $148.00 to $146.00.
• 5/8/2026 – Gilead Sciences had its “buy” rating reaffirmed by Truist Financial Corporation. They now have a $157.00 price target on the stock, up from $155.00.
• 5/8/2026 – Gilead Sciences had its price target lowered by Royal Bank Of Canada from $123.00 to $122.00. They now have a “sector perform” rating on the stock.
• 4/28/2026 – Gilead Sciences had its price target raised by Morgan Stanley from $171.00 to $175.00. They now have an “overweight” rating on the stock.
• 4/17/2026 – Gilead Sciences had its price target raised by The Goldman Sachs Group, Inc. from $125.00 to $130.00. They now have a “neutral” rating on the stock.
• 4/13/2026 – Gilead Sciences had its price target raised by Citigroup Inc. from $156.00 to $165.00. They now have a “buy” rating on the stock.

Gilead Sciences Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, June 29th. Stockholders of record on Monday, June 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Monday, June 15th. Gilead Sciences’s dividend payout ratio (DPR) is currently 44.69%.

Insider Activity

In other news, insider Johanna Mercier sold 28,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $131.29, for a total value of $3,676,120.00. Following the transaction, the insider owned 125,779 shares of the company’s stock, valued at approximately $16,513,524.91. This trade represents a 18.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Friday, May 15th. The shares were sold at an average price of $132.27, for a total transaction of $396,810.00. Following the completion of the transaction, the chief financial officer directly owned 173,191 shares in the company, valued at approximately $22,907,973.57. This represents a 1.70% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 68,000 shares of company stock valued at $9,047,570. Company insiders own 0.30% of the company’s stock.

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.